PMID- 38023226
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - The efficacy and safety of 5-fluorouracil/cisplatin/vincristine as a multi-agent 
      chemotherapy regimen in gestational trophoblastic neoplasia.
PG  - 1240972
LID - 10.3389/fonc.2023.1240972 [doi]
LID - 1240972
AB  - OBJECTIVE: To determine the efficacy and safety of the 5-fluorouracil (5-FU), 
      cisplatin, and vincristine (FPV) chemotherapy regimen in patients with 
      gestational trophoblastic neoplasia (GTN). METHODS: We performed a retrospective 
      study of 96 GTN patients with International Federation of Gynecology and 
      Obstetrics (FIGO) scores of 5 or greater in the Second Affiliated Hospital of 
      Zhengzhou University from October 2013 to October 2019, including 54 patients who 
      received FPV chemotherapy and 42 who received 5-FU/actinomycin D/vincristine 
      (FAV) chemotherapy. A pulsed intravenous device was used to administer 5-FU. The 
      clinical characteristics, adverse events, and response rates were compared 
      between the groups. RESULTS: The patients in the FPV and FAV groups received a 
      total of 228 and 190 courses of chemotherapy, respectively. Complete response 
      (CR) was found in 88.89% (48/54) and 90.48% (38/42) of patients in the FPV group 
      and FAV group, respectively (p = 0.801). Both chemotherapy regimens yielded CR in 
      all low-risk patients (100% vs. 100%), whereas 86.67% and 88.24% of high-risk 
      patients achieved CR (FPV vs. FAV, p = 0.836), respectively. The most common 
      adverse events (AEs) were myelosuppression and gastrointestinal reactions 
      including neutropenia (83.97%), anemia (60.05%), and nausea (46.41%). In 
      comparison to those in the FAV group, patients in the FPV group reported higher 
      rates of grade 1/2 nausea (53.51% vs. 37.89%, p = 0.001), hepatotoxicity (28.95% 
      vs. 17.89%, p = 0.008), oral mucositis (23.25% vs. 10.53%, p = 0.001), and grade 
      3/4 neutropenia (47.37% vs. 27.37%, p < 0.001), while grade 1/2 diarrhea (7.46% 
      vs. 13.68%, p = 0.037) and grade 3/4 oral mucositis (0 vs. 6.32%, p < 0.001) were 
      much more common in the FAV group. The rate of overall survival at 5 years was 
      96.8% in the FPV group and 97.3% in the FAV group (p = 0.760), whereas the 5-year 
      disease-free survival rates were 95.9% and 93.9% (p = 0.754), respectively. 
      CONCLUSION: The FPV and FAV regimens with pulsed intravenous 5-FU yielded 
      comparable CR rates and tolerability in patients with GTN with FIGO scores of >5. 
      Further randomized controlled trials are warranted to validate their efficacy.
CI  - Copyright (c) 2023 Wang, Wang, Xu, Yang and Wang.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
AD  - Henan Provincial Clinical Research Center for Gynecological and Obstetrical 
      Disease (Gynecological Oncology), Zhengzhou, China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
AD  - Henan Provincial Clinical Research Center for Gynecological and Obstetrical 
      Disease (Gynecological Oncology), Zhengzhou, China.
FAU - Xu, Zhen
AU  - Xu Z
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
AD  - Henan Provincial Clinical Research Center for Gynecological and Obstetrical 
      Disease (Gynecological Oncology), Zhengzhou, China.
FAU - Yang, Linli
AU  - Yang L
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
AD  - Henan Provincial Clinical Research Center for Gynecological and Obstetrical 
      Disease (Gynecological Oncology), Zhengzhou, China.
FAU - Wang, Wuliang
AU  - Wang W
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
AD  - Henan Provincial Clinical Research Center for Gynecological and Obstetrical 
      Disease (Gynecological Oncology), Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20231031
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10644366
OTO - NOTNLM
OT  - FAV
OT  - efficacy
OT  - gestational trophoblastic neoplasia
OT  - multi-agent chemotherapy
OT  - pulsed intravenous
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/01/01
CRDT- 2023/11/29 15:42
PHST- 2023/06/29 00:00 [received]
PHST- 2023/10/10 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 15:42 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1240972 [doi]
PST - epublish
SO  - Front Oncol. 2023 Oct 31;13:1240972. doi: 10.3389/fonc.2023.1240972. eCollection 
      2023.